Diagnostics
-
Justin Sullivan via Getty Images
Labcorp expands Epic pact to make full test menu available on Aura
The Labcorp agreement continues the expansion of Aura, which gives healthcare providers access to tests from companies including Quest Diagnostics.
By Nick Paul Taylor • May 14, 2026 -
Alamy
Roche to acquire digital pathology firm PathAI for up to $1.05B
Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
By Elise Reuter • May 7, 2026 -
Explore the Trendlineâž”
Permission granted by Boston Scientific
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
Permission granted by Baxter
Top medtech executive moves in 2026
Hologic, Teleflex, Grail and others are welcoming new CEOs, while STAAR Surgical is searching for its next leader. Read MedTech Dive’s roundup for all the details.
By Susan Kelly • May 4, 2026 -
Courtesy of Thermo Fisher Scientific
Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg
The private equity group plans to accelerate growth of the acquired business, including by empowering it to engage in M&A.
By Nick Paul Taylor • April 28, 2026 -
Permission granted by Butterfly Network
ProfileWith ultrasound on a chip, Butterfly Network aims for global reach
Butterfly, which makes handheld imaging machines, hopes to make the technology accessible to more patients with its pricing and AI features.
By Elise Reuter • April 27, 2026 -
Permission granted by CathWorks
Medtronic closes $585M purchase of CathWorks
The deal is the second tuck-in acquisition this year for Medtronic, which has signaled its intent to pursue more M&A in its core business lines.
By Susan Kelly • April 20, 2026 -
Courtesy of Siemens Healthineers
Siemens plans shareholder vote on Siemens Healthineers spinoff
The German parent, which is giving up its majority stake in Siemens Healthineers, said preparations for the transaction are progressing toward a vote at its February annual meeting.
By Susan Kelly • April 17, 2026 -
Courtesy of Exact Sciences
Abbott lowers earnings forecast after $21B Exact Sciences buy
CEO Robert Ford said the companies are a good cultural fit and he expects demand for Exact’s colon cancer screening test to increase.
By Elise Reuter • April 16, 2026 -
Retrieved from Hologic on April 06, 2026
Hologic CEO Steve MacMillan to retire after go-private deal
The $18.3 billion acquisition by Blackstone and TPG is expected to close Tuesday.
By Elise Reuter • April 6, 2026 -
Justin Sullivan via Getty Images
Labcorp closes purchase of New York pathology reference lab assets
The deal, which will see Labcorp run 12 patient service centers, is part of the company’s ongoing efforts to expand through acquisitions.
By Nick Paul Taylor • March 23, 2026 -
Courtesy of Exact Sciences/Business Wire
Abbott to close $21B Exact Sciences acquisition Monday
Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.
By Elise Reuter • March 20, 2026 -
Courtesy of Grail
Grail CEO Bob Ragusa to retire
Josh Ofman, company president, will step into the top job. Guggenheim Securities analysts said the leadership change “has been in development for some time and is unrelated to the NHS trial readout."
By Nick Paul Taylor • March 16, 2026 -
Getty Images
Genetic tests come under scrutiny in Trump administration’s fraud crackdown
As the Centers for Medicare and Medicaid Services calls for public feedback on how to stop lab test fraud, experts say a tailored regulatory strategy will be key to avoid stifling innovation.
By Susan Kelly • March 12, 2026 -
Permission granted by Agilent
Agilent to buy Biocare Medical for $950M
Biocare’s strong growth in immunohistochemistry is expected to strengthen Agilent’s ability to develop new in vitro diagnostic antibodies.
By Susan Kelly • March 9, 2026 -
Courtesy of Labcorp
Labcorp expands PathAI pact to roll out digital pathology platform in US
Labcorp’s pathologists will use the software to review, interpret and manage digital images of slides for primary diagnosis.
By Nick Paul Taylor • Feb. 25, 2026 -
Courtesy of Business Wire
Guardant buys MetaSight for $59M upfront to acquire blood test tech
MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.
By Nick Paul Taylor • Feb. 23, 2026 -
Getty Images
Grail’s multi-cancer early detection test misses study goal
Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in Stage III and IV cancers.
By Susan Kelly • Feb. 20, 2026 -
Stringer via Getty Images
GE HealthCare, BARDA ink $35M expansion to AI-enabled imaging deal
The jointly funded project positions GE HealthCare to develop ultrasound technologies that non-expert users can operate.
By Nick Paul Taylor • Feb. 18, 2026 -
Getty Images
Danaher to buy Masimo for $9.9B to boost diagnostics portfolio
Masimo’s board considered other potential partners before determining Danaher was an “ideal fit,” executives at the patient monitoring company said.
By Susan Kelly • Feb. 17, 2026 -
Courtesy of Siemens Healthineers
Siemens Healthineers, Mayo Clinic partner on neurodegenerative disease, cancer
An expanded collaboration between the two organizations will focus on prostate cancer and metastatic liver tumors, in addition to certain neurological disorders.
By Susan Kelly • Feb. 13, 2026 -
Justin Sullivan via Getty Images
Labcorp closes takeover of Empire City assets to fuel New York expansion
The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.
By Nick Paul Taylor • Feb. 11, 2026 -
Sarah Silbiger via Getty Images
FDA breakthrough program starts FY2026 at steady pace
Orthopedics was the most active area over the second half of 2025, with the FDA issuing 13 breakthrough designations to devices in the therapeutic area.
By Nick Paul Taylor • Feb. 9, 2026 -
Getty Images
Genetic testing takes greater share of Medicare Part B test spending: OIG
Spending on the tests, which analyze genetic material from both people and pathogens, rose 20% year over year in 2024, the analysis found.
By Susan Kelly • Feb. 4, 2026 -
Courtesy of Grail
Grail files for FDA approval of multi-cancer early detection test
Premarket approval could help the company secure coverage from commercial payers and Medicare.
By Nick Paul Taylor • Feb. 2, 2026 -
Permission granted by Cleveland Diagnostics
Cleveland Diagnostics names Michael Iskra CEO
Iskra will help Cleveland Diagnostics scale up commercial adoption of its IsoPSA blood-based test that analyzes the structure of protein biomarkers for prostate cancer signals.
By Susan Kelly • Jan. 29, 2026
